The Claim

Continued treatment with once-weekly tirzepatide (10 or 15 mg) for 52 weeks following a 36-week open-label lead-in period maintains and augments weight reduction in adults with obesity (BMI ≥30) or overweight (BMI ≥27 with a weight-related complication) without diabetes, resulting in a mean additional weight loss of 5.5% from randomization, while switching to placebo leads to a mean weight regain of 14.0% over the same period, for a difference of 19.4 percentage points (95% CI, -21.2% to -17.7%; P < .001).

Source: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
88score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Quantitative
1 study reviewed
In plain English

In adults with obesity or overweight but not diabetes, taking tirzepatide for a full year after an initial 9-month treatment period results in an average additional weight loss of 5.5%, while stopping the drug and taking a placebo leads to an average weight regain of 14.0%. The difference between these groups is 19.4 percentage points, which is statistically significant.

See the scientific wording

Continued treatment with once-weekly tirzepatide (10 or 15 mg) for 52 weeks following a 36-week open-label lead-in period maintains and augments weight reduction in adults with obesity (BMI ≥30) or overweight (BMI ≥27 with a weight-related complication) without diabetes, resulting in a mean additional weight loss of 5.5% from randomization, while switching to placebo leads to a mean weight regain of 14.0% over the same period, for a difference of 19.4 percentage points (95% CI, -21.2% to -17.7%; P < .001).

Why this might work

Tirzepatide activates two types of receptors in the brain and body that naturally control appetite and blood sugar. This activation reduces hunger, improves how the body uses energy, and helps maintain a lower body weight over time.

Supported mechanismbased on 1 study

What the research says

1 study
  1. Study: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.

    This study shows that people who keep taking the tirzepatide injection for a year after initial weight loss lose a bit more weight, while those who stop regain a lot of weight, exactly as the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.